LivingGLP1
Descriptive only

HbA1c below 7 percent

Type 2 diabetes (adults); background therapy: prandial, premixed or basal bolus insulin with or without other drugs

weeks 36 to 64 (target week 52)Not stated by the trialsDoses of a drug pooledOdds ratio
1
Randomized trials
2
Treatments
174
Participants
76
Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
OTHER_ACTIVE_basal_bolus_insulinOTHER_ACTIVE_basal_insulin_sglt2i
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
Baseline effect modifiers and prognostic factors per trial
TrialBaseline HbA1c (percent)
effect modifier, prognostic factor; 1 of 1
Background glucose lowering therapy (stratum S0 to S4)
effect modifier, prognostic factor; 1 of 1
Diabetes duration (years)
effect modifier, prognostic factor; 1 of 1
BEYOND
S002277
8.57S317.07

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
  • NoteData handling, input conversions: count_from_percent 2
Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
BEYOND52.14per_protocolHbA1c below 7.0 percent; Table 3 prints this row under the 7.5 percent labelnot statednot statednot_statednot statednot statedopen_labelnon_industry2019age over 35; HbA1c above 7.5 percent; basal bolus insulin 6 months or more; eGFR 60 or more

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the odds ratio on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
BEYONDA1OTHER_ACTIVE_basal_bolus_insulin52.14arm, responders45 / 99count_from_percentR0022468:Table 3
BEYONDA3OTHER_ACTIVE_basal_insulin_sglt2i52.14arm, responders31 / 75count_from_percentR0022468:Table 3

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab